Combination therapy with efavirenz, nelfinavir, and nucleoside reverse- transcriptase inhibitors in children infected with human immunodeficiency virus type 1

New England Journal of Medicine

Volumn 341, Issue 25, 1999, Pages 1874-1881

  Starr, Stuart E ^h   Fletcher, Courtney V ^a   Spector, Stephen A ^b   Yong, Florence H ^c   Fenton, Terence ^c   Brundage, Richard C ^a   Manion, Douglas ^d   Ruiz, Nancy M ^d   Gersten, Merril ^e   Becker, Mark ^e   McNamara, James ^f   Mofenson, Lynne M ^g   Purdue, Lynette ^f   Siminski, Suzanne ^c   Graham, Bobie ^c   Kornhauser, David M ^c   Fiske, William ^c   Vincent, Carol ^j   Lischner, Harold W ^j   Dankner, Wayne M ^b   Flynn, Patricia M ⁱ   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d DUPONT COMPANY   (United States)

^e AGOURON PHARMACEUTICALS INC   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁱ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^j St Jude Hospital for Children ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

ADOLESCENT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; NELFINAVIR; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 0033576814     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199912163412502     Document Type: Article

References (23)

1. Melvin AJ, Mohan KM, Arcuino LA, Edelstein RE, Frenkel LM. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997;16:968-74.
2. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B. Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 1997;11:F107-F111.
3. Kline MW, Fletcher CV, Harris AT, et al. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosinc (ddI) in children infected with the human immunodeficiency virus. J Pediatr 1998;132:543-6.
4. Wintergerst U, Hoffmann F, Sölder B, et al. Comparison of two anti-retroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus. Pediatr Infect Dis J 1998;17:495-9.
5. Yogev R, Stanley K, Nachman SA, et al. Virologic efficacy of ZDV-3TC vs d4T-ritonavir (RTV) vs ZDV-3TC-RTV in stable antiretroviral experienced children (Pediatric ACTG Trial 338). In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28-October 1,1997. Washington, D.C.: American Society for Microbiology, 1997:LB-6. abstract.
6. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997;336:1343-9.
7. Young SD, Britcher SF, Tran LO, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995;39: 2602-5.
8. Adkins JC, Noble S. Efavirenz. Drugs 1998;56:1055-64.
9. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep 1998;47(RR-4):1-43. [Erratum, MMWR Morb Mortal Wkly Rep 1998;47:315.]
10. Fiske WD, Benedek IH, White SJ, et al. Pharmacokinetic interaction between DMP 266 and nelfinavir mesylate (NFV) in healthy volunteers. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28-October 1, 1997. Washington, D.C.: American Society for Microbiology, 1997:275. abstract.
11. Calvelli T, Denny TN, Paxton H, Gelman R, Kagan J. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 1993;14:702-15.
12. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34: 187-220.
15. Dibley MJ, Goldsby JB, Staehling NW, Trowbridge FL. Development of normalized curves for the international growth reference: historical and technical considerations. Am J Clin Nutr 1987;46:736-48.
16. Wei LJ, Johnson WE. Combining dependent tests with incomplete repeated measurements. Biometrika 1985;72:359-64.
17. Zar JH. Biostatistical analysis. 2nd ed. Englewood Cliffs, N.J.: Prentice-Hall, 1984:113.
18. Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, 1975.
19. Sustiva (efavirenz capsules). Wilmington, Del.: Dupont Pharmaceuticals, September 1998 (package insert).
20. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999;28:1109-18.
21. Berhane R, Bagenda D, Marum L, et al. Growth failure as a prognostic indicator of mortality in pediatric HIV infection. Pediatrics 1997;100:126. abstract.
22. McKinney RE Jr, Wilfert C, AIDS Clinical Trials Group Protocol 043 Study Group. Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. J Pediatr 1994; 125:728-33.
23. Yong FH, Stanley K, McKinney RE, et al. Prognostic value of plasma RNA, CD4, and growth markers for clinical disease progression in children with HIV disease. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 24-27, 1998. Washington, D.C.: American Society for Microbiology, 1998:364. abstract.